23:33 , Apr 25, 2017 |  BC Extra  |  Company News

Management tracks

Eye disease company Ophthotech Corp. (NASDAQ:OPHT) said co-founder and CEO David Guyer will become executive chairman, effective July 1. President and CFO Glenn Sblendorio will become CEO and remain president. Ophthotech promoted SVP of Finance...
00:39 , Nov 22, 2016 |  BC Week In Review  |  Clinical News

AGIL-AADC regulatory update

FDA granted rare pediatric disease designation to Agilis’ AGIL-AADC to treat Aromatic L-Amino Acid Decarboxylase (AADC) deficiency. The product is an adeno-associated viral (AAV) vector encoding the dopa decarboxylase (DDC; AADC) gene. Agilis Biotherapeutics LLC...
07:00 , Sep 13, 2016 |  BC Extra  |  Company News

Management tracks

Gene therapy company NightstaRx Ltd. (London, U.K.) named Gregory Robinson CSO. He was CSO at Agilis Biotherapeutics LLC (Cambridge, Mass.). Wound care company Acelity L.P. Inc. (San Antonio, Texas) said EVP and CFO Tom Casey...
07:00 , Oct 12, 2015 |  BC Week In Review  |  Company News

University of South Florida, Agilis Biotherapeutics deal

The university granted Agilis exclusive, worldwide rights to develop and commercialize Reelin (RELN) replacement technologies to treat cognitive disorders. Agilis will provide research funding to the university. The university deferred questions Agilis, which declined to...
07:00 , Jun 15, 2015 |  BC Week In Review  |  Company News

University of South Florida, Agilis Biotherapeutics deal

The university granted Agilis exclusive, worldwide rights to develop and commercialize UBE3a gene therapies to treat Angelman syndrome. The university will receive an undisclosed upfront payment, plus undisclosed milestones and royalties. University of South Florida...
08:00 , Dec 8, 2014 |  BC Week In Review  |  Company News

Agilis Biotherapeutics management update

Agilis Biotherapeutics LLC , Germantown, Md.   Business: Neurology, Gene/Cell therapy   Hired: Greg Robinson as CSO, formerly senior director of rare diseases business development at Shire plc  ...
07:00 , Sep 15, 2014 |  BC Week In Review  |  Company News

Agilis Biotherapeutics management update

Agilis Biotherapeutics LLC , Germantown, Md.   Business: Neurology, Gene/Cell therapy   Hired: Mark Pykett as president and CEO, formerly president and CEO of Navidea Biopharmaceuticals Inc.  ...
07:00 , Aug 11, 2014 |  BioCentury  |  Emerging Company Profile

AAVLife: Fixing Friedreich's heart

AAVLife S.A.S. is developing an adeno-associated viral vector-based gene therapy that could become the first disease-modifying treatment for Friedreich's ataxia-associated cardiomyopathy. The therapy has the potential to decrease the risk of cardiac events and improve...
08:00 , Jan 6, 2014 |  BC Week In Review  |  Company News

Agilis Biotherapeutics, Intrexon deal

On Dec. 31, 2013, Agilis and Intrexon partnered to develop DNA-based gene therapies and genetically modified cell therapies for Friedreich's ataxia (FRDA), a rare neurodegenerative disease caused by a genetic mutation that reduces the expression...
08:00 , Jan 6, 2014 |  BC Week In Review  |  Company News

Agilis Biotherapeutics management update

Agilis Biotherapeutics LLC , Germantown, Md.   Business: Neurology, Gene/Cell therapy   Hired: George Zorich as CEO, formerly president of North American operations at Bioniche Pharma Holdings Ltd. , which Mylan Inc. acquired  ...